Jacob Gitta, Fassbinder Eva, Klein Jan Philipp
GAIA, Hans-Henny-Jahnn-Weg 53, 22085, Hamburg, Deutschland.
Zentrum für Integrative Psychiatrie Kiel, Klinik für Psychiatrie und Psychotherapie, Christian-Albrechts-Universität zu Kiel, Kiel, Deutschland.
Nervenarzt. 2025 Jul 22. doi: 10.1007/s00115-025-01856-0.
Digital health applications (DiGA) for borderline personality disorder (BPD) are still a relatively new and underresearched topic but hold great potential, especially considering that there is no single approved medication for BPD. So far, one DiGA (priovi) has been permanently approved for BPD by the Federal Institute for Drugs and Medical Devices (BfArM). Concerns related to this topic mainly relate to patient safety and the lack of a therapeutic relationship; however, studies on priovi have actually shown positive findings regarding the therapeutic relationship and its use seems to increase safety rather than compromise it. That said, there is still a significant need for further research in this field. In the practical application each clinician must consider the individual situation of their patient and integrate a DiGA into the treatment plan in a way that seems to best suit the specific patient's needs.
用于边缘型人格障碍(BPD)的数字健康应用程序(DiGA)仍是一个相对较新且研究不足的课题,但具有巨大潜力,尤其是考虑到目前尚无针对BPD的单一获批药物。到目前为止,一种DiGA(priovi)已被联邦药品和医疗器械研究所(BfArM)永久批准用于BPD。与该主题相关的担忧主要涉及患者安全和缺乏治疗关系;然而,关于priovi的研究实际上已显示出在治疗关系方面的积极结果,并且其使用似乎会提高安全性而非损害安全性。话虽如此,该领域仍迫切需要进一步研究。在实际应用中,每位临床医生都必须考虑其患者的个体情况,并以最适合特定患者需求的方式将DiGA纳入治疗计划。
Nervenarzt. 2025-7-22
Cochrane Database Syst Rev. 2012-8-15
Psychopharmacol Bull. 2024-7-8
Cochrane Database Syst Rev. 2022-9-26
Cochrane Database Syst Rev. 2006-1-25
Cochrane Database Syst Rev. 2022-11-14
J Med Internet Res. 2024-11-29
Int J Ment Health Nurs. 2022-8
Psychiatr Serv. 2019-5-29